| |
PO2095 Open Label, Limited Access Protocol of Posaconazole in Invasive Fungal Infections
Principal Investigator: Mark W. Brunvand, MD
Protocol Number: RMBMT-114
Major Objectives
The study is designed to evaluate the safety of Posaconazole under an open-label, limited access study for subjects with invasive fungal infections.
Patient Selection
Inclusion Criteria:
- Adults (age ≥ 18 years) of either gender and of any race.
- Children (age ≥ 13) years of either gender and of any race.
- The subject or his/her legally authorized representative have given signed, written informed consent, or the informed consent was obtained.
- Ability to take study medication orally by swallowing or via an enteral feeding tube.
- Subject is willing and able to adhere to dose schedules and mandatory procedures.
- A proven, probable or possible invasive fungal infection which is refractory to standard antifungal therapies.
Exclusion Criteria:
Females who are pregnant or nursing
|
|
